nach oben

Erschienen in:

01.03.2005 | Original Research Article

Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor Therapy

verfasst von: Alexandra E. Rätz Bravo, Lydia Tchambaz, Anita Krähenbühl-Melcher, Lorenzo Hess, Raymond G. Schlienger, Dr Stephan Krähenbühl

Erschienen in: Drug Safety | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Background: Drug-drug interactions (DDIs) are a well known risk factor for adverse drug reactions. HMG-CoA reductase inhibitors (‘statins’) are a cornerstone in the treatment of dyslipidaemia and patients with dyslipidaemia are concomitantly treated with a variety of additional drugs. Since DDIs are associated with adverse reactions, we performed a cross-sectional study to assess the prevalence of potentially critical drug-drug and drug-statin interactions in an outpatient adult population with dyslipidaemia.

Methods: Data from patients with dyslipidaemia treated with a statin were collected from 242 practitioners from different parts of Switzerland. The medication list was screened for potentially harmful DDIs with statins or other drugs using an interactive electronic drug interaction program.

Results: We included 2742 ambulatory statin-treated patients (mean age ± SD 65.1 ± 11.1 years; 61.6% males) with (mean ± SD) 3.2 ± 1.6 diagnoses and 4.9 ± 2.4 drugs prescribed. Of those, 190 patients (6.9%) had a total of 198 potentially harmful drug-statin interactions. Interacting drugs were fibrates or nicotinic acid (9.5% of patients with drug-statin interactions), cytochrome P450 (CYP) 3A4 inhibitors (70.5%), digoxin (22.6%) or ciclosporin (cyclosporine) [1.6%]. The proportion of patients with a potential drug-statin interaction was 12.1% for simvastatin, 10.0% for atorvastatin, 3.8% for fluvastatin and 0.3% for pravastatin. Additionally, the program identified 393 potentially critical non-statin DDIs in 288 patients.

Conclusions: CYP3A4 inhibitors are the most frequent cause of potential drug interactions with statins. As the risk for developing rhabdomyolysis is increased in patients with drug-statin interactions, clinicians should be aware of the most frequently observed drug-statin interactions and how these interactions can be avoided.

Fijn R, Van den Bemt PM, Chow M, et al. Hospital prescribing errors: epidemiological assessment of predictors. Br J Clin Pharmacol 2002; 53(3): 326–31PubMedCrossRef

Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277(4): 301–6PubMedCrossRef

Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289(13): 1652–8PubMedCrossRef

Grymonpre RE, Mitenko PA, Sitar DS, et al. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 1988; 36(12): 1092–8PubMed

Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001; 15(6): 897–918PubMedCrossRef

Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356(9242): 1667–71PubMedCrossRef

Hoffman HS. The interaction of lovastatin and warfarin [letter]. Conn Med 1992; 56(2): 107PubMed

Tanaka H, Matsumoto K, Ueno K, et al. Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother 2003; 37(2): 178–81PubMedCrossRef

Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64(1): 123–8PubMedCrossRef

10.

Federman DG, Hussain F, Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 2001; 94(10): 1023–6PubMed

11.

Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. Am J Med 2000; 108(4): 351–2PubMedCrossRef

12.

Heerey A, Barry M, Ryan M, et al. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000; 169(3): 176–9PubMedCrossRef

13.

Horsmans Y. Differential metabolism of statins: importance in drug-drug interactions. Eur Heart J Suppl 1999; 1Suppl. T: T7–T12

14.

Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000; 23(3): 197–213PubMedCrossRef

15.

Rogers JF, Nafziger AN, Bertino Jr JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113(9): 746–50PubMedCrossRef

16.

Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111 (5): 390–400CrossRef

17.

Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57(5): 357–64PubMedCrossRef

18.

Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36(2): 288–95PubMedCrossRef

19.

Klasco RK, Moore L, editors. Drug-Reax® system. Greenwood Village (CO): Micromedex (edition expired 2002 Jun)

20.

Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58(11): 773–8PubMed

21.

Gaddis GM, Holt TR, Woods M. Drug interactions in at-risk emergency department patients. Acad Emerg Med 2002; 9(11): 1162–7PubMedCrossRef

22.

Langdorf MI, Fox JC, Marwah RS, et al. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 2000; 7(11): 1321–9PubMedCrossRef

23.

Steering Committee ICH. ICH harmonised tripartitude guideline: clinical safety data management: definitions and standards for expedited Reporting E2A. Geneva: The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 1994: 1–10

24.

Stockley IH, editor. Drug interactions. 5th ed. London: The Pharmaceutical Press, 1999

25.

Tatro DS, editor. Drug Interaction Facts™. St Louis (MO): Facts and Comparisons, updated 2003 Jan

26.

Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist 1979; 6: 65–70

27.

Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31(1): 53–9PubMedCrossRef

28.

Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108(8): 921–4PubMedCrossRef

29.

Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92(3): 285–8PubMedCrossRef

30.

Wooltorton E. Bayer pulls cerivastatin (Baycol) from market [news]. CMAJ 2001; 165(5): 632PubMed

31.

Einarson TR, Metge CJ, Iskedjian M, et al. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther 2002; 24(12): 2126–36PubMedCrossRef

32.

Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41(5): 343–70PubMedCrossRef

33.

Sakaeda T, Takara K, Kakumoto M, et al. Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J Pharm Pharmacol 2002; 54(3): 419–23PubMedCrossRef

34.

Triscari J, Swanson BN, Willard DA, et al. Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 1993; 36(3): 263–5PubMedCrossRef

35.

Bogman K, Peyer AK, Torok M, et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132(6): 1183–92PubMedCrossRef

36.

Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51(5): 461–70PubMedCrossRef

37.

Yamreudeewong W, DeBisschop M, Martin L, et al. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003; 26(6): 421–38PubMedCrossRef

38.

Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274(52): 37161–8PubMedCrossRef

39.

Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001; 297(3): 861–7PubMed

40.

Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42(13): 1141–60PubMedCrossRef

41.

Shitara Y, Itoh T, Sato H, et al. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304(2): 610–6PubMedCrossRef

42.

Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25(4): 2732–4PubMed

43.

Kyrklund C, Backman JT, Neuvonen M, et al. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73(6): 538–44PubMedCrossRef

44.

Rosholm JU, Bjerrum L, Hallas J, et al. Polypharmacy and the risk of drug-drug interactions among Danish elderly: a prescription database study. Dan Med Bull 1998; 45(2): 210–3PubMed

45.

Hohl CM, Dankoff J, Colacone A, et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38(6): 666–71PubMedCrossRef

46.

Cleland JG, Baksh A, Louis A. Polypharmacy (or polytherapy) in the treatment of heart failure. Heart Fail Monit 2000; 1(1): 8–13PubMed

47.

Burnakis TG, Mioduch HJ. Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia. Arch Intern Med 1984; 144(12): 2371–2PubMedCrossRef

48.

Chan TY, Critchley JA. Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements. Drug Saf 1992; 7(2): 159–61PubMedCrossRef

49.

Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 709–17PubMedCrossRef

50.

Wrenger E, Muller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327(7407): 147–9PubMedCrossRef

51.

Schepkens H, Vanholder R, Billiouw JM, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110(6): 438–41PubMedCrossRef

52.

Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003; 138(11): 917–24PubMed

53.

Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1979; 1(4): 365–74PubMedCrossRef

54.

Pennell DJ, Nunan TO, O’Doherty MJ, et al. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol [letter]. Lancet 1984; I(8374): 463CrossRef

55.

Samanta A, Burden AC. Fever, myalgia, and arthralgia in a patient on captopril and allopurinol [letter]. Lancet 1984; I(8378): 679CrossRef

56.

Ahmad S. Allopurinol and enalapril: drug induced anaphylactic coronary spasm and acute myocardial infarction [letter]. Chest 1995; 108(2): 586PubMedCrossRef

57.

Kumar A, Edward N, White MI, et al. Allopurinol, erythema multiforme, and renal insufficiency. BMJ 1996; 312(7024): 173–4PubMedCrossRef

58.

Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29(1): 82–7PubMedCrossRef

59.

Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 72(9): 835–47PubMedCrossRef

60.

Sproule BA, Naranjo CA, Brenmer KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997; 33(6): 454–71PubMedCrossRef

61.

Skerritt U, Evans R, Montgomery SA. Selective serotonin reuptake inhibitors in older patients: a tolerability perspective. Drugs Aging 1997; 10(3): 209–18PubMedCrossRef

62.

Guck TP, Elsasser GN, Kavan MG, et al. Depression and congestive heart failure. Congest Heart Fail 2003; 9(3): 163–9PubMedCrossRef

63.

Puckett Jr WH, Visconti JA. An epidemiological study of the clinical significance of drug-drug interactions in a private community hospital. Am J Hosp Pharm 1971; 28(4): 247–53PubMed

64.

Schuster BG, Fleckenstein L, Wilson JP, et al. Low incidence of adverse drug reactions due to drug-drug interaction in a potentially high risk population of medical inpatients [abstract]. Clin Res 1982; 30: 258A

Titel: Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor Therapy
verfasst von: Alexandra E. Rätz Bravo
Lydia Tchambaz
Anita Krähenbühl-Melcher
Lorenzo Hess
Raymond G. Schlienger
Dr Stephan Krähenbühl
Publikationsdatum: 01.03.2005
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 3/2005
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200528030-00007

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor Therapy

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

Do Selective Cyclo-Oxygenase-2 Inhibitors Have a Future?

Tolerability of Paracetamol

Protease Inhibitor-Induced Diabetic Complications

Tibolone and Endometrial Cancer

Extrapyramidal Symptoms with Atypical Antipsychotics

Identification of Priorities for Medication Safety in Neonatal Intensive Care